

A05: Drug-related treatment

Purpose of collecting these data:

This module aims to collect qualitative and quantitative data on persons accessing treatment services, disaggregated by socio-demographic variables, by drug type and type of treatment (pharmacological, psychosocial and rehabilitation and aftercare services). One use of these data is to measure the extent of treatment coverage for those suffering from drug use disorders, one component of SDG indicator 3.5.1 on the coverage of treatment interventions for substance use disorders.

Item	Type	Description	Response options	Definitions / Specific instructions	Disaggregation	Metadata	Justifications
Ranking and trends in the provision of treatment	I	Ranking of drug groups based on their relevance in terms of primary drug for which treatment is demanded.	1,2,3,...	Glossary	<ul style="list-style-type: none"> • Drug type: cannabis, Opioids (heroin, non-prescription opioids, other), cocaine type, amphetamines (amphetamine, methamphetamine), ecstasy-type, sedatives and tranquilizers, NPS (specify), others (specify). • Sex 	Information on the procedure used for the qualitative assessment: specify number of experts, affiliation, method (e.g. Delphi). Primary sources used for the qualitative assessment: <ul style="list-style-type: none"> • national data (specify collection method) • periodic government report (link) • specific study (link) • expert assessment • other (specify) 	UNGASS: Paras 1a, j Para 4 (a), 6 (c) 10 (a,b), 16 (a), 20, 21 EWG: - include questions on pathway of referral - collect data on the number of people in treatment - collect data on the quality and type of treatment - data by gender and vulnerable groups related to the different aspects of services available - obtain qualitative assessments of poly-drug use - define broader categories of drugs
		Trends in the provision of drug treatment relative to the previous reporting year for each drug group and/or drug defined.	Large increase, Some increase, Stable, Some decrease, Large decrease, Unknown	Glossary			
New developments	I	Specification of changes that might have occurred in the reporting year in terms of drug treatment, e.g.: - major increase or decrease in the number of people treated, - development of new forms of treatment services, etc.	Free text	Developments for specific drug groups/types to be provided if the information is available	<i>Not applicable</i>		
Treatment coverage	I	Assessment of the coverage of treatment interventions (pharmacological, psychosocial and rehabilitation and aftercare services) for substance use disorders	Statistical Data	Coverage = People in treatment / People with drug use disorders	<ul style="list-style-type: none"> • Type of intervention - Pharmacological - Psychosocial - Rehabilitation and aftercare • Sex 		
		- Proportion of people who need treatment and receive it (SDG 3.5.1).	Statistical Data				
Qualitative assessment of polydrug use	II	Specification of the most common combinations of drugs for which people are seeking treatment	List of primary and secondary drugs <i>(adapted version of list L1 on drug</i>	Drugs to be chosen from a dropdown menu			

			<i>classes and types for prevalence related questions).</i>				
Availability of data on treatment	I	Availability of information/data treatment for drug use	Yes, No, Unknown	If the answer to the question is NO, the respondent skips the next part.	<i>Not applicable</i>	<i>Not applicable</i>	
Number of people in treatment by primary drug and intervention	II	Total number of people in treatment by primary drug and intervention during the reference period	Statistical Data	<ul style="list-style-type: none"> • Total number of people in treatment (first-time entrants, continuous clients and re-entering). Drug treatment is defined as a process designed to achieve a desired health status for patients suffering from drug use disorders. Treatment is provided by qualified professionals, in the framework of recognised medical, psychological or social assistance practice. • People (cases, clients) in treatment: people who are in treatment for the use of drugs in the estimate year. <u>First-time entrants:</u> People who have entered treatment in the reporting year for the first-time. <u>Re-entering</u>-people who have previously been in treatment and are currently in treatment but might have been out of treatment for a certain period, including the previous year. <u>Continuous clients</u>- clients who are continuing treatment from last year and might have been in treatment previously as well. • Treatment episode: the number of times a person commences and ends a treatment service in the estimate year, number of admissions within the estimate year. 	<ul style="list-style-type: none"> • <i>Source of referral</i> <ul style="list-style-type: none"> - court/probation/police; - GP; - self/friends/family; - healthcare/treatment facility; - educational services; - other; - not known • <i>Treatment Intervention</i> <ul style="list-style-type: none"> • Pharmacological <ul style="list-style-type: none"> - Detoxification - Opioid antagonist maintenance - Other antagonist treatment (to be specified) • Psychosocial <ul style="list-style-type: none"> - counselling - cognitive behavioural therapy - social support - other • Rehabilitation and - aftercare <ul style="list-style-type: none"> - interventions based on scientific evidence and focused on the process of rehabilitation, - recovery and social reintegration - other • <i>Age:</i><18, 18-24, 25-64,>65 • <i>Sex</i> 	<ul style="list-style-type: none"> • Counting unit Treatment versus episodes (the questionnaire will state preference for client data relative to data on episodes) • Entry status <ul style="list-style-type: none"> - first time-entrants, - continuous and - re-entering clients - total • Geographical coverage: National vs sub-national, # provinces / states, % of national target population covered • Reference period • Data source • Expert opinion: Evaluation of the reported figures relative to the total number of people in treatment Low <=25% Medium 25-75% High =>75 % 	<p>PoA: Provision of data for 1h and 4.h: developing a comprehensive treatment system offering a wide range of integrated pharmacological (such as detoxification and opioid agonist and antagonist maintenance) and psychosocial (such as counselling, cognitive behavioural therapy and social support) interventions based on scientific evidence and focused on the process of rehabilitation, recovery and social reintegration;</p>

			<p><u>Source of referral</u>-pathway of referral meaning the institution or person/s who led the client to seek treatment Data on all people (clients) in treatment is preferable. Alternatively, please provide data on first-time entrants and/or people re-entering treatment, and/or people in continuous treatment. When no data on clients (people who receive treatment for the use of drug/s) is available, data on treatment episodes is to be collected.</p> <p>Primary drug is the main drug causing disorders and leading the patient to seek treatment.</p> <p>Secondary drugs-additional drugs used in combination with the primary drug.</p> <p>Treatment coverage by intervention (3.5.1): Number of people in treatment by the type of treatment facilities identified by the service interventions which they provide in order to identify the numerator of the indicator capturing SDG goal 3.5.1 on the coverage of treatment interventions. <u>Pharmacological interventions</u> include detoxification and opioid agonist and antagonist Maintenance; <u>Psychosocial interventions</u> include (such as counselling, cognitive behavioural therapy and social support); and <u>Rehabilitation and aftercare interventions</u> include interventions based on</p>	<ul style="list-style-type: none"> • Drug type (as defined above) 		
--	--	--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------	--	--

				scientific evidence and focused on the process of rehabilitation, recovery and social reintegration <i>Sources: EMCDDA, WHO, International Standards on Treatment</i>		
Treatment in relation to polydrug use	II	Total cases where drugs other than the primary drug are counted in the reported figures.	Statistical Data	Polydrug use: The use of a main drug in combination with additional drug/s.	<ul style="list-style-type: none"> • Drug class: cannabis, opioids (opiates), cocaine, amphetamines, ecstasy type, NPS, sedatives and tranquilizers, others. 	
		Proportion of reported figures that capture polydrug use				
Access to treatment for specific groups of the population	III	Number of clients by Socio-economic characteristics.	Statistical Data	Glossary	<ul style="list-style-type: none"> • Living status • Educational attainment • Employment Status • Sex 	<p>PoA: 6a Provision of data to enhance the commitment to respect, protect and promote human rights, fundamental freedoms and inherent dignity of all individuals and the rule of law in the development and implementation of drug policies also targeted at vulnerable groups.</p> <p>EWG: - develop an information system that can measure the impact rather than only the process - increased granularity of the information sources that allows for the analysis of gender disparity and vulnerable groups</p>
	III	Number of clients by specific groups of the population	Statistical Data	<p>Total number of clients by sub-population groups. <i>Sources WHO UNODC International Standards for the treatment of drug use disorders, UNODC 2016: 5.1; 3.1.7</i></p> <p>Instruction: If no quantitative data is available, an assessment of the coverage of treatment for the mentioned groups is to be provided (approximate proportion of treatment coverage for sub-population groups as a percentage of all people in treatment)</p>	<p>Specific groups:</p> <ul style="list-style-type: none"> • Persons with disabilities • People living in rural areas • Indigenous people • Migrants/internally displaced persons • Homeless people • Sex workers • Other (specify) 	

							UNGASS: Para 4 a,d,g (gender), 4 i (indigenous people) PoA:8b
Availability of studies / research / surveys	III	Link to any studies, reports, surveys or other research on drug use (including poly-drug use) in the general population, and/or within specific groups of people in vulnerable situations in your country in the last 5 years	Provide link		<i>Not applicable</i>	<i>Not applicable</i>	